C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, announced its participation in the 7th Annual Targeted Protein Degradation & Induced Proximity Summit from October 28-31, 2024, in Boston. Four company leaders will deliver presentations and participate in panel discussions, showcasing C4T's expertise in developing orally bioavailable degraders.
Key presentations include:
- CEO Andrew Hirsch in a panel on strategic outlook for the field
- CSO Stew Fisher on leveraging kinetics-based PKPD modeling for degrader optimization
- CMO Len Reyno presenting initial clinical data for CFT1946
- CBO Scott Boyle participating in two panels on strategic partnership deals
These presentations aim to demonstrate C4T's potential to transform patients' lives through their innovative approach to protein degradation science.
C4 Therapeutics (Nasdaq: CCCC), un'azienda biofarmaceutica in fase clinica focalizzata sulla degradazione mirata delle proteine, ha annunciato la sua partecipazione al 7° Summit Annuale sulla Degradazione Mirata delle Proteine e Prossimità Indotta dal 28 al 31 ottobre 2024, a Boston. Quattro leader dell'azienda terranno presentazioni e parteciperanno a discussioni di panel, mostrando l'expertise di C4T nello sviluppo di degradatori bio disponibili per via orale.
Le presentazioni chiave includono:
- Il CEO Andrew Hirsch in un panel sulla prospettiva strategica del settore
- Il CSO Stew Fisher su come sfruttare la modellazione PKPD basata sulla cinetica per l'ottimizzazione dei degradatori
- Il CMO Len Reyno che presenta dati clinici iniziali per CFT1946
- Il CBO Scott Boyle che partecipa a due panel sui contratti di partnership strategica
Queste presentazioni mirano a dimostrare il potenziale di C4T di trasformare le vite dei pazienti attraverso il loro approccio innovativo alla scienza della degradazione delle proteine.
C4 Therapeutics (Nasdaq: CCCC), una empresa biofarmacéutica en etapa clínica centrada en la degradación dirigida de proteínas, anunció su participación en la 7ª Cumbre Anual sobre Degradación Dirigida de Proteínas y Proximidad Inducida del 28 al 31 de octubre de 2024, en Boston. Cuatro líderes de la empresa darán presentaciones y participarán en discusiones en paneles, mostrando la experiencia de C4T en el desarrollo de degradadores bio disponibles por vía oral.
Las presentaciones clave incluyen:
- El CEO Andrew Hirsch en un panel sobre la perspectiva estratégica del campo
- El CSO Stew Fisher sobre cómo aprovechar la modelización PKPD basada en cinética para la optimización de degradadores
- El CMO Len Reyno presentando datos clínicos iniciales para CFT1946
- El CBO Scott Boyle participando en dos paneles sobre acuerdos de asociación estratégica
Estas presentaciones tienen como objetivo demostrar el potencial de C4T para transformar la vida de los pacientes a través de su enfoque innovador en la ciencia de degradación de proteínas.
C4 Therapeutics (Nasdaq: CCCC), 표적 단백질 분해에 중점을 둔 임상 단계의 생명공학 회사가 2024년 10월 28일부터 31일까지 보스턴에서 열리는 제7회 연례 표적 단백질 분해 및 유도 근접 정상회담에 참여한다고 발표했습니다. 회사의 네 명의 리더가 발표를 하고 패널 토론에 참여하며, 경구 생체 이용 가능한 분해자 개발에 대한 C4T의 전문성을 보여줄 것입니다.
주요 발표 내용은 다음과 같습니다:
- CEO Andrew Hirsch가 이 분야에 대한 전략적 전망 패널에 참여
- CSO Stew Fisher가 분해자 최적화를 위한 동역학 기반 PKPD 모델링 활용에 대해 발표
- CMO Len Reyno가 CFT1946에 대한 초기 임상 데이터를 발표
- CBO Scott Boyle이 전략적 파트너십 계약에 대한 두 개의 패널에 참여
이 발표는 C4T의 혁신적인 단백질 분해 과학 접근 방식을 통해 환자들의 삶을 변화시킬 수 있는 잠재력을 보여주는 것을 목표로 합니다.
C4 Therapeutics (Nasdaq: CCCC), une entreprise biopharmaceutique en phase clinique axée sur la dégradation ciblée des protéines, a annoncé sa participation au 7ème Sommet Annuel sur la Dégradation Ciblée des Protéines et la Proximité Induite du 28 au 31 octobre 2024, à Boston. Quatre dirigeants de l’entreprise réaliseront des présentations et participeront à des discussions en panel, mettant en avant l'expertise de C4T dans le développement de dégradateurs bio disponibles par voie orale.
Les présentations clés incluent :
- Le PDG Andrew Hirsch dans un panel sur les perspectives stratégiques du secteur
- Le CSO Stew Fisher sur l'optimisation des dégradateurs via la modélisation PKPD basée sur la cinétique
- Le CMO Len Reyno présentant des données cliniques initiales sur CFT1946
- Le CBO Scott Boyle participant à deux panels sur des accords de partenariat stratégiques
Ces présentations visent à démontrer le potentiel de C4T à transformer la vie des patients grâce à leur approche innovante en matière de science de la dégradation des protéines.
C4 Therapeutics (Nasdaq: CCCC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Proteinabbau konzentriert, hat seine Teilnahme am 7. jährlichen Gipfel über gezielten Proteinabbau und induzierte Nähe vom 28. bis 31. Oktober 2024 in Boston bekannt gegeben. Vier Unternehmensleiter werden Präsentationen halten und an Podiumsdiskussionen teilnehmen und so die Expertise von C4T in der Entwicklung von oral bioverfügbaren Abbauprodukten demonstrieren.
Wichtige Präsentationen umfassen:
- CEO Andrew Hirsch in einem Panel über die strategische Perspektive des Feldes
- CSO Stew Fisher zu Kinetik-basiertem PKPD-Modellierung zur Optimierung von Abbauprodukten
- CMO Len Reyno, der erste klinische Daten zu CFT1946 präsentiert
- CBO Scott Boyle, der an zwei Panels über strategische Partnerschaftsverträge teilnimmt
Diese Präsentationen zielen darauf ab, das Potenzial von C4T zu zeigen, das Leben von Patienten durch ihren innovativen Ansatz in der Wissenschaft des Proteinabbaus zu transformieren.
- Participation in a major industry summit, showcasing the company's expertise
- Presentation of initial clinical data for CFT1946, indicating progress in drug development
- Multiple company leaders presenting, demonstrating depth of expertise across the organization
- None.
WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its participation in the 7th Annual Targeted Protein Degradation & Induced Proximity Summit, to be held October 28-31, 2024, in Boston, MA. Four members of the company’s leadership team will deliver oral presentations or participate on panels to demonstrate the company’s expertise in designing and developing highly catalytic orally bioavailable degraders that have the potential to transform patients’ lives.
Details of the company’s participation are as follows:
Tuesday, October 29, 2024
Panel Discussion: CEO Think Tank: A Strategic Look at Targeted Protein Degradation & Induced Proximity Field
Time: 9:30 am ET
C4T Participant: Andrew Hirsch, president and chief executive officer
Oral Presentation: Clinical Insights on Leveraging Kinetics-Based PKPD Modeling to Drive Degrader Optimization
Time: 11:30 am ET
C4T Presenter: Stew Fisher, Ph.D., chief scientific officer
Wednesday, October 30, 2024
Oral Presentation: Initial Clinical Data from the Ongoing Clinical Trial of CFT1946
Time: 8:30 am ET
C4T Presenter: Len Reyno, M.D., chief medical officer
Panel Discussion: Lessons Learned from a Major Strategic Partnership Deal for a Platform
Time: 4:10 pm ET
C4T Participant: Scott Boyle, Ph.D., chief business officer
Panel Discussion: Lessons Learned from a Major Strategic Partnership Deal for an Asset
Time: 4:55 pm ET
C4T Participant: Scott Boyle, Ph.D., chief business officer
Additional information about the 7th Annual Targeted Protein Degradation & Induced Proximity Summit, including an overview for each of the above sessions, is available on the conference website.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
What is C4 Therapeutics (CCCC) presenting at the 7th Annual Targeted Protein Degradation Summit?
When and where is C4 Therapeutics (CCCC) participating in the Targeted Protein Degradation Summit?
Who from C4 Therapeutics (CCCC) is presenting at the Targeted Protein Degradation Summit?
